St Jude's vascular closure device gets FDA approval:
This article was originally published in Clinica
St Jude Medical has received US FDA approval to market its 6F Angio-Seal vascular closure device, used to seal arterial punctures created during interventional cardiology procedures. The device includes new enhancement techniques that further simplify deployment, eliminating the need to dilate the arterial puncture site. Angio-Seal devices have successfully penetrated the European market and are expected to have a strong impact in the US, said the St Paul, Minneapolis-based company.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.